Radioimmunoscintigraphy of colorectal carcinoma with a 111In-labelled anti-TAG-72 monoclonal antibody. 1993

A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
Department of Nuclear Medicine, Clinic Hospital, Barcelona, Spain.

Radioimmunoscintigraphy (RIS) of colorectal carcinoma with a 111In-labelled anti-TAG-72 monoclonal antibody (CYT-103) has been performed in 24 patients with five primary lesions and 10 suspicious of recurrence (in one of these patients two RIS were made). Histopathological confirmation of the disease and surgical liver examination were carried out in all primary tumours and in 12 possible recurrences. In the remaining eight patients a final diagnosis was established according to the clinical course and other diagnostic procedures. Planar and tomographic scans were obtained at 48 and 72 h postinjection in all patients. All primary tumours were detected by RIS. In the group with recurrences confirmed pathologically the results were nine true positive, two true negative and one false positive in a patient affected only with liver disease. The nine true positive studies corresponded to four positive by computed tomography (CT), four negative by CT and one nonconclusive by CT. Surgical liver examination results were 15 true negative and two false negative. No correlation was found between serum levels of carcinoembryonic antigen or TAG-72 and the detection of the lesions. In 10 patients human anti-mouse antibody (HAMA) levels were studied. In conclusion, RIS with an anti-TAG-72 monoclonal antibody is a useful technique for the study and localization of colorectal tumours, mainly in cases of recurrence, being also indicated in patients with normal TAG-72 serum levels.

UI MeSH Term Description Entries
D007205 Indium Radioisotopes Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes. Radioisotopes, Indium
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D016719 Radioimmunodetection Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera. Immunoscintigraphy, Radiolabeled,Radioimmunoimaging,Radioimmunoscintigraphy,Immunoscintigraphy, Radiolabelled,Radiolabeled Immunoscintigraphy,Radiolabelled Immunoscintigraphy,Immunoscintigraphies, Radiolabeled,Immunoscintigraphies, Radiolabelled,Radioimmunodetections,Radioimmunoimagings,Radioimmunoscintigraphies,Radiolabeled Immunoscintigraphies,Radiolabelled Immunoscintigraphies

Related Publications

A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
February 1999, Nuclear medicine communications,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
September 1993, Nuclear medicine communications,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
August 1993, European journal of nuclear medicine,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
November 1993, European journal of nuclear medicine,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
February 1994, Nuclear medicine communications,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
June 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
June 1996, European journal of nuclear medicine,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
February 1995, British journal of urology,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
March 1992, Nuclear medicine communications,
A Muxí, and F Pons, and R Herranz, and F Novell, and R Fernández, and X Filella, and A García, and M Solá, and M Trías, and J Setoain
October 1986, Nuclear medicine communications,
Copied contents to your clipboard!